We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

ProBioGen Introduces “Pathway Modulator Technology”
Product News

ProBioGen Introduces “Pathway Modulator Technology”

ProBioGen Introduces “Pathway Modulator Technology”
Product News

ProBioGen Introduces “Pathway Modulator Technology”

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ProBioGen Introduces “Pathway Modulator Technology”"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProBioGen has announced the implementation of its new “Pathway Modulator Technology”, a permanent modification of animal cell lines for substantially improved protein yields.

The Pathway Modulator Technology is royalty-free and available for new and existing cell lines either in service projects or as a license.

The Pathway Modulator Technology is highly versatile and quick: It is readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity.

The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells.

Upon stable transfection, the modulator enzymes’ concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs.

For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification enhanced yields between 1.5 and 2.6-fold.

The Pathway Modulator Technology can be installed into any existing cell lines, avoiding an entire new cell line development. It lowers upstream manufacturing costs and speeds up drug development through a more rapid supply of larger quantities of bulk drug substance.

The Pathway Modulator Technology can be freely combined with other parts of ProBioGen’s Tool Box, including the GlymaxX® ADCC Enhancement Technology, the stable CHO Evaluation Platform with DG44 and K1 cell lines, and the companies’ Full Pharmaceutical CHO Expression and Media Platform.

ProBioGen is actively seeking biopharmaceutical companies with hard-to-make protein drugs or with cell lines of insufficient productivities, to challenge their current yields.